This paper describes work to develop a novel human antibody nasal spray as a prophylactic treatment against SARS-CoV-2. Formulations were developed at two protein concentrations and assessed for delivery using an Aptar VP3 nasal spray pump. Both formulations were shown to be suitable for nasal delivery in terms of pH, osmolality, and delivered droplet size; no evidence of protein agglomeration was observed as a result of spraying. Further studies are planned to investigate the stability of the developed products and to establish pharmacokinetics and pharmacodynamics.
Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery
This Might Also Be of Interest
Why Pharma should care about circular packaging – Futurity leading the way
Publications, Pharmaceutical, Sustainability, Device Innovations, Brand Differentiation, Product Solutions
Navigating the Development for Orally Inhaled and Nasal Drug Products
Publications, Pharmaceutical, Device Innovations, Market Insights, Product Solutions
Using Intranasal Delivery for Drug Repositioning: A Compelling Proposition for Lifecy...
Publications, Pharmaceutical, Device Innovations, Brand Differentiation, Market Insights, Product Solutions
The Potential and Challenge of Nasal Vaccination
Publications, Pharmaceutical, Device Innovations, Brand Differentiation, Market Insights, Product Solutions
